このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Automated Oxygen Titration With the EMILY.AI Device During the Six-Minute Walk Test

2026年11月16日 更新者:Aether Tech S.L.

Functional, Clinical, and Predictive Validation Study of the EMILY AI Device in Patients With Acute and Chronic Respiratory Failure: Exercise Substudy (Six-Minute Walk Test) in Ambulatory Patients

This study evaluates EMILY.AI, an investigational (non-CE-marked) smart oxygen valve that automatically adjusts the oxygen flow delivered to a patient.

Adults with chronic respiratory disease who need oxygen during exertion perform two six-minute walk tests on the same day, 30 minutes apart: one with oxygen adjusted automatically by EMILY.AI and one with a fixed oxygen flow delivered through the same device. The order is randomized and participants do not know which test uses automatic titration.

The study compares the time spent within the target saturation range, desaturation, oxygen use, walking distance, breathlessness and participant preference between the two tests. This substudy is part of clinical investigation FJD-EMILY-23-02, whose other substudies are registered in separate records.

調査の概要

状態

募集

条件

介入・治療

詳細な説明

Background Patients with chronic respiratory disease often desaturate during exertion, and fixed-flow oxygen cannot follow the rapid changes in oxygen demand during walking and recovery. EMILY.AI combines a medical-grade oxygen valve with a rule-based algorithm that sets the oxygen flow.

Design Pilot, pragmatic, single-blind, randomized crossover study at Hospital Universitario Fundación Jiménez Díaz (Madrid, Spain). Each participant performs two supervised six-minute walk tests (6MWT) according to the American Thoracic Society guideline, separated by 30 minutes of rest: one with automatic titration by EMILY.AI and one with a fixed flow set by the physician, delivered through the same device so that the participant cannot tell them apart. The order of the two tests is randomized. Each test includes 6 minutes of walking and 2 minutes of standardized recovery.

Safety The medical team knows the device configuration and supervises the valve throughout each test.

Measurements SpO2, heart rate and respiratory rate are recorded with medical-grade pulse oximeters (Nonin, Masimo or Nihon Kohden models), together with distance walked, Borg dyspnoea score, oxygen delivered and participant-reported comfort, breathlessness and preference.

The protocol FJD-EMILY-23-02 also includes a substudy in the Respiratory Intermediate Care Unit and a substudy in a conventional hospital ward, registered separately.

研究の種類

介入

入学 (推定)

24

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

  • 名前:Alba Naya Prieto, MD
  • 電話番号:+34 915 50 48 00
  • メール:alba.naya@fjd.es

研究連絡先のバックアップ

  • 名前:Sarah Beatrice Heili Frades, MD, PhD
  • 電話番号:+34 915 50 48 00
  • メール:SHeili@fjd.es

研究場所

      • Madrid、スペイン、28040
        • 募集
        • Hospital Universitario Fundación Jiménez Díaz
        • コンタクト:
          • Sarah Beatrice Heili Frades Zimmermann MD, PhD
          • 電話番号:+34 915 50 48 00
          • メール:SHeili@fjd.es
        • コンタクト:
          • Alba Naya Prieto, MD
          • 電話番号:+34 915 50 48 00
          • メール:alba.naya@fjd.es
        • 主任研究者:
          • Sarah Beatrice Heili Frades Zimmermann, MD, PhD

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

40年~90年 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  • Aged 40 to 90 years with a chronic respiratory disease.
  • Indication for exertional oxygen therapy, defined as SpO2 below 88% during a six-minute walk test and/or resting respiratory failure (PaO2 below 60 mmHg).
  • Able to understand the study and sign informed consent.

Exclusion Criteria:

  • Decompensated acute or chronic disease with severe organ involvement, such as cardiovascular disease.
  • Musculoskeletal or neurological disease preventing stable and safe walking.
  • Comorbidities or treatments that, by intensity or dose, limit performance of the tests or interpretation of the results (such as alcohol use, beta-blockers, or other neurological or psychiatric drugs).
  • Walking limitation preventing the six-minute walk test, or cardiovascular or connective tissue disease limiting accurate transcutaneous pulse oximetry.
  • Pregnancy or breastfeeding (women of childbearing potential require a negative pregnancy test at screening).

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:クロスオーバー割り当て
  • マスキング:独身

武器と介入

参加者グループ / アーム
介入・治療
実験的:EMILY.AI first, then fixed flow

First 6MWT with automatic titration by EMILY.AI; after 30 minutes of rest, second 6MWT with fixed-flow oxygen through the same device.

Standard care: constant oxygen flow set by the physician, delivered through the EMILY.AI device in fixed mode so that the participant cannot distinguish it from automatic titration.

Investigational smart oxygen valve with rule-based algorithm that adjusts oxygen flow every second from pulse-oximetry SpO2, heart rate and respiratory rate during walking and recovery.

他の名前:
  • EMILY.AI Smart Valve
実験的:Fixed flow first, then EMILY.AI

First 6MWT with fixed-flow oxygen through the device; after 30 minutes of rest, second 6MWT with automatic titration by EMILY.AI.

Standard care: constant oxygen flow set by the physician, delivered through the EMILY.AI device in fixed mode so that the participant cannot distinguish it from automatic titration.

Investigational smart oxygen valve with rule-based algorithm that adjusts oxygen flow every second from pulse-oximetry SpO2, heart rate and respiratory rate during walking and recovery.

他の名前:
  • EMILY.AI Smart Valve

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Percentage of time with SpO2 within the target range
時間枠:Day 1

Percentage of test time (6 minutes of walking plus 2 minutes of recovery) with SpO2, measured by pulse oximetry, within the predefined target range (88-92%), without delivering oxygen while SpO2 is above the range. Compared between the test with automatic titration by EMILY.AI and the test with fixed flow.

Day 1

二次結果の測定

結果測定
メジャーの説明
時間枠
Percentage of test time with SpO2 below 88%
時間枠:Day 1

Percentage of test time (walking and recovery) with SpO2 below 88%, compared between conditions.

Day 1
Number of desaturation episodes with SpO2 below 88%
時間枠:Day 1

Number of episodes per test in which SpO2 falls below 88%, compared between conditions.

Day 1
Time to start of oxygen flow correction
時間枠:Day 1

Time in seconds from SpO2 leaving the target range (88-96%) to the start of an oxygen flow change, compared between conditions.

Day 1
Time to return of SpO2 to the target range
時間枠:Day 1

Time in seconds from SpO2 leaving the target range (88-96%) to its return to the range, compared between conditions.

Day 1
Percentage of test time with oxygen delivered while SpO2 is above 92%
時間枠:Day 1

Percentage of test time (walking and recovery) during which oxygen is delivered while SpO2 is above 92%, compared between conditions.

Day 1
Number of episodes with oxygen delivered while SpO2 is above 92%
時間枠:Day 1

Number of episodes per test in which oxygen is delivered while SpO2 is above 92%, compared between conditions.

Day 1
Total oxygen delivered
時間枠:Day 1

Total volume of oxygen delivered (litres) during each test including recovery, compared between conditions.

Day 1
Mean oxygen flow
時間枠:Day 1

Mean oxygen flow (litres per minute) delivered during each test including recovery, compared between conditions.

Day 1
Six-minute walk distance
時間枠:Day 1

Distance walked (metres), compared between conditions.

Day 1
Change in dyspnoea measured with the modified Borg Dyspnoea Scale
時間枠:Day 1: before and immediately after each six-minute walk test

Change from the start to the end of each test in dyspnoea measured with the modified Borg Dyspnoea Scale, which ranges from 0 (no breathlessness at all) to 10 (maximal breathlessness). Higher scores mean a worse outcome. Compared between conditions.

Day 1: before and immediately after each six-minute walk test
Maximum heart rate
時間枠:Day 1

Maximum heart rate (beats per minute) during each test, compared between conditions.

Day 1
Maximum respiratory rate
時間枠:Day 1

Maximum respiratory rate (breaths per minute) during each test, compared between conditions.

Day 1
Perceived difference in exercise capacity between the two tests
時間枠:Day 1: within 1 hour after the second six-minute walk test

Number of participants answering no, partially or yes to the question "Did you notice differences in your exercise capacity in either of the two tests?", and, if so, in which test. Categorical 3-option response, not a scored scale.

Day 1: within 1 hour after the second six-minute walk test
Perceived difference in breathlessness between the two tests
時間枠:Day 1: within 1 hour after the second six-minute walk test

Number of participants answering no, partially or yes to the question "Did you notice differences in shortness of breath in either of the two tests?", and, if so, in which test. Categorical 3-option response, not a scored scale.

Day 1: within 1 hour after the second six-minute walk test
Perceived difference in comfort of oxygen delivery between the two tests
時間枠:Day 1: within 1 hour after the second six-minute walk test

Number of participants answering no, partially or yes to the question "Did you notice differences in the comfort of oxygen delivery in either of the two tests?", and, if so, in which test. Categorical 3-option response, not a scored scale.

Day 1: within 1 hour after the second six-minute walk test
Preference between the two oxygen delivery systems
時間枠:Day 1: within 1 hour after the second six-minute walk test

Number of participants answering no, partially or yes to the question "Do you prefer either of the two oxygen systems used in the tests?", and, if so, which one. Categorical 3-option response, not a scored scale.

Day 1: within 1 hour after the second six-minute walk test
Preference for continuous automatic flow regulation at home
時間枠:Day 1: within 1 hour after the second six-minute walk test

Number of participants answering no, partially or yes to the question "Would you prefer your home oxygen system to regulate the oxygen flow continuously?". Categorical 3-option response, not a scored scale.

Day 1: within 1 hour after the second six-minute walk test
Preference for telemonitored home oxygen
時間枠:Day 1: within 1 hour after the second six-minute walk test

Number of participants answering no, partially or yes to the question "Would you prefer your home oxygen system to be telemonitored by the medical team?". Categorical 3-option response, not a scored scale.

Day 1: within 1 hour after the second six-minute walk test

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

協力者

捜査官

  • 主任研究者:Sarah Beatrice Heili Frades, MD, PhD, MD, PhD、Hospital Universitario Fundación Jiménez Díaz

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2026年4月15日

一次修了 (推定)

2026年12月20日

研究の完了 (推定)

2026年12月20日

試験登録日

最初に提出

2026年10月28日

QC基準を満たした最初の提出物

2026年11月11日

最初の投稿 (実際)

2026年11月16日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月18日

QC基準を満たした最後の更新が送信されました

2026年11月16日

最終確認日

2026年11月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • FJD-EMILY-23-02-TM6M
  • FJD-EMILY-23-02 (その他の識別子:Aether Tech SL)

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

未定

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。